CRISPR Therapeutics already has financial backing from Celgene and in October announced a discovery alliance with Vertex in cystic fibrosis. Novartis has a stake in rivals Intellia Therapeutics ...

ERS Genomics ('ERS'), which was established to provide broad access to the foundational CRISPR/Cas9 intellectual property ...

The CRISPR Technology Market is experiencing tremendous growth due to development in gene editing, rising applications in drug discovery, and growing agricultural biotechnology. Investment in ...

CRISPR technology, driven by Cas9, redefines gene editing, facilitating targeted DNA modifications that advance genetic ...

Dr. Francis Collins, a renowned geneticist, and former longtime director of the National Institutes of Health, is retiring ...

The future of medicine with CRISPR and CAR-T therapy, exploring ethical, societal, and accessibility challenges in healthcare ...

A proof-of-concept study shows that CRISPR-Cas9 can eliminate extra chromosome copies in Down syndrome cells. The method restores normal gene function but is not yet ready for human trials. Scientists ...

Artificial-intelligence tools and community science can help in places where data are scarce, so long as funding for data collection does not falter in the future.

Take CRISPR Therapeutics (NASDAQ: CRSP) and Intellia Therapeutics (NASDAQ: NTLA), two biotechs specializing in gene editing. Finance, is $83.60; the latter earns a price target of $50.80 from ...